![]() |
![]() |
![]() |
![]() |
![]() |
![]() |


Research Associate
During his postdoctoral work at The Neuro, Carl studied the major Amyotrophic Lateral Sclerosis disease gene C9ORF72. Through an antibody validation pipeline that he developed, Carl characterized all known C9ORF72 commercial antibodies and found that the most cited antibody does not recognize the protein in any application, but had been cited in dozens of papers cited thousands of times. Carl and Peter McPherson are further developing the pipeline as a technology solution, along with a sustainable business model, to address the antibody liability crisis. The technology platform, called the NeuroSGC Antibody Characterization Platform, is now being formally implemented at The Neuro through the creation of an Antibody Characterization Group. This group functions in partnership with ten leading antibody/KO cell manufacturers who are distinguished by a commitment to reagent quality and contribute significant cash and in-kind resources to the initiative.
Publicatons CLaflamme
N Biotechnol. 2021 65:1-8. doi: 10.1016/j.nbt.2021.07.001
PMID: 34246180
Elife. 2019 8:. doi: 10.7554/eLife.48363
PMID: 31612854
2023
F1000Res. 07.08.2023 12:308. doi: 10.12688/f1000research.131333.1
PMID: 37545650
2022
F1000Res. 07.12.2022 11:977. doi: 10.12688/f1000research.124632.2
PMID: 36415206
2021
N Biotechnol. 07.07.2021 65:1-8. doi: 10.1016/j.nbt.2021.07.001
PMID: 34246180
2019
Elife. 15.10.2019 8:. doi: 10.7554/eLife.48363
PMID: 31612854